TD Cowen Raises Mirum Pharmaceuticals (MIRM) Price Target to $145
Key Points
- TD Cowen maintained a Buy rating on Mirum Pharmaceuticals, Inc. on October 21, 2026, moving its price target up to $145 from $140.
- TD Cowen's $145 price target implies 74.91% upside from Mirum Pharmaceuticals, Inc.'s ($MIRM) current $82.90 share price.
- Mirum Pharmaceuticals recently traded around $82.90, sitting below its 50-day moving average of $92.11.
- Wall Street maintains a strong buy consensus on the stock, supported by 14 analyst opinions and a mean price target of $153.43.
Since the rating, $MIRM is down 0.1% to date (from the $83.44 close on Oct 21, 2026).
Get Mirum Pharmaceuticals text alerts
We text you when insiders, Congress, analysts or big funds move on $MIRM.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Mirum Pharmaceuticals, Inc. alert may contain errors. Disclosures
On October 21, 2026, TD Cowen maintained its Buy rating on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) while raising its price target from $140 to $15.00. The research note provides a fresh look at the biopharmaceutical developer's growth path as shares trade near the middle of their 52-week range. Mirum Pharmaceuticals closed at $83.44 on the day of the announcement. TD Cowen's upward revision places its target below the wider Wall Street consensus average, though it remains well above where the shares recently traded.
MIRM
Mirum Pharmaceuticals, Inc.
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
TD Cowen's Call on Mirum Pharmaceuticals
In its October 21, 2026 note, TD Cowen kept a Buy rating on the stock and bumped its target up to $145 from $140. The firm's updated target joins a string of recent adjustments from major financial houses tracking the rare disease drug maker.
Other Institutional Activity in Mirum Pharmaceuticals
Large funds continue to adjust their holdings in the biotechnology firm. Frazier Life Sciences Management, L.P. held steady with 7,679,684 shares worth about $636.26 million. Jupiter Topco LLC grew its holdings by 2,954,592 shares, ending with 5,909,184 shares worth about $489.58 million. William Blair Investment Management, LLC grew its holdings by 1,069,072 shares, ending with 1,404,741 shares worth about $116.38 million.
Mirum Pharmaceuticals, Inc. Stock Down 0.6%
Mirum recently traded around $82.90 as of October 22, 2026. The stock closed at $83.44 on October 21, 2026. Shares sit below the 50-day moving average of $92.11 and below the 200-day moving average of $98.61. The company carries a market capitalization of roughly $5.38 billion and a beta of 0.62, pointing to lower volatility than the broader market.
$MIRM price target
Mirum Pharmaceuticals, Inc. daily closes and this analyst's $145 target. Not advice.
Recent Earnings
For the trailing twelve months, Mirum generated $618.07 million in revenue with a trailing EPS of -$14.10. The company reported a year-over-year revenue growth rate of 37.9%. Its next earnings release is scheduled for November 4, 2026.
Insider Buying and Selling at Mirum Pharmaceuticals, Inc.
Company insiders have made several stock dispositions in recent months. Officer Jolanda Marie Howe sold 40,000 shares on August 18, 2026, at an average price of $100.00 for a total value of $4,000,000. Chief Executive Officer Christopher Peetz sold 30,000 shares on September 1, 2026, for a total value of $2,960,401. Jolanda Marie Howe later sold 658 shares on September 2, 2026, at an average price of $100.00 for a total value of $65,800. Chief Financial Officer Eric H Bjerkholt sold 9,943 shares on September 14, 2026, at an average price of $98.37 for a total value of $978,093.
Analysts Set New Price Targets
Several other firms updated their views ahead of TD Cowen's note. On October 12, 2026, Citigroup maintained a Buy rating and moved its target from $160.00 to $184.00. Evercore ISI Group maintained an Outperform rating on October 13, 2026, raising its target from $135.00 to $146.00. Morgan Stanley maintained an Overweight rating on October 13, 2026, lifting its target from $137.00 to $152.00. Stifel maintained a Buy rating on October 15, 2026, taking its target from $136.00 to $156.00. Analyst opinions lean positive, with a consensus recommendation of a strong buy and a mean price target of $153.43 across 14 tracked opinions.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a Foster City, California-based biotechnology company focused on developing and commercializing treatments for rare and orphan diseases. Its flagship product, LIVMARLI, treats cholestatic pruritus in patients with Alagille syndrome. The firm relies on expanding its rare disease portfolio as it works toward profitability.
Bottom Line
Investors will look ahead to the company's earnings report on November 4, 2026, for updates on revenue growth and drug pipeline progress. Watch for further analyst revisions and institutional filing updates as the year closes out.
Related Filing Alerts
Source: TD Cowen's rating change on $MIRM (Oct 21, 2026). Written by software, not financial advice. How we make alerts